Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
Heinrich
Michael C
MC
Department of Medicine, Oregon Health Science University Cancer Institute, Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA.
Corless
Christopher L
CL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000235:genetics / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000235:genetics / Q000378:metabolism; D012509:Sarcoma / Q000188:drug therapy* / Q000201:enzymology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000201:enzymology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor